The formulation for sustained release tablet of Epinedium component was selected and the evaluation equation of in vitro release was established. The liquidity of component was improved with the help of colloidal silica aided by spray drying, which would be the main drug in the sustained release tablets. Dissolution was selected as an evaluation index to investigate skeletal material type, fillers, impact porogen, lubricants and other materials on the quality of sustained release tablet. The sustained release tablets were prepared by dry compression. Formulation of sustained release preparations was main drug 35%, HPMC K(4M) 20% and HPMC K(15M) 10% as skeleton material, MCC 31% as filler, PEG6000 2% as porogen and magnesium stearate 2% as lubricant. The sustained release tablets released up to 80% in 8 h. The zero order equation, primary equation and Higuchi equation could simulate the release characteristics of sustained release tablets in vitro, the correlation coefficients r were larger than 0.96. The primary equation was most similar in vitro release characteristics and its correlation coefficient r was 0.9950. The preparation method is simple and the results of formulation selection are reliable. It can be used to guide the production of Epimedium component sustained release preparations.
Download full-text PDF |
Source |
---|
Drug Dev Ind Pharm
January 2025
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.
Objective: The present study aims to develop and evaluate the voriconazole-loaded thermoresponsive hydrogel using tools.
Methods: Poloxamer 407 and PEG 400 were selected as the components from studies for thermoresponsive hydrogel of voriconazole. The cohesive energy density (CED) and solubility parameters (SP) were calculated using Biovia Material Studio 2022 software to predict the polymer-polymer miscibility and drug-polymer miscibility.
Soft Matter
January 2025
Department of Chemistry and Chemical Biology, Indian Institute of Technology (ISM), Dhanbad-826004, India.
Drug delivery vehicles optimize therapeutic outcomes by enhancing drug efficacy, minimizing side effects, and providing controlled release. Injectable hydrogels supersede conventional ones in the field of drug delivery owing to their less invasive administration and improved targeting. However, they face challenges such as low biodegradability and biocompatibility, potentially compromising their effectiveness.
View Article and Find Full Text PDFFront Transplant
January 2025
Department of Surgical, Medical, Biomolecular Pathology and Intensive Care, University of Pisa, Pisa, Italy.
Background And Aims: There is growing interest in the environmental impact of surgical procedures, yet more information is needed specifically regarding liver transplantation. This study aims to quantify the total greenhouse gas emissions, or carbon footprint, associated with adult whole-size liver transplantation from donors after brain death, including the relevant back-table graft preparation.
Methods: The carbon footprint was calculated retrospectively using a bottom-up approach.
Adv Compos Hybrid Mater
January 2025
J. Mike Walker '66 Department of Mechanical Engineering, Texas A&M University, College Station, TX 77843 USA.
Dosage tolerance is one of the translational challenges of using metformin (Met) in brain therapeutics. This paper presents metal-organic framework (MOF)-74-Mg nanocarriers (NCs) for intranasal (IN) delivery of brain-specific agents with a prolonged release time. We confirmed their excellent biocompatibility (5 mg/mL) and intrinsic fluorescence properties (370/500 nm excitation/emission peak) in Neuro-2A cells.
View Article and Find Full Text PDFACS Appl Mater Interfaces
January 2025
Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, Republic of Korea.
Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin cancer with limited treatment options, often associated with Merkel cell polyomavirus (MCPyV) and marked by hypoxic tumor microenvironments that promote resistance to therapies. Belzutifan, an FDA-approved hypoxia-inducible factor-2α (HIF-2α) inhibitor, has shown promise in inhibiting tumor growth; however, its clinical efficacy is hindered by its low solubility, rapid clearance, and limited bioavailability. In this study, we present a strategy using porous silicon (pSi) microparticles and nanoparticles as carriers for the sustained delivery of benzoate to MCC cells.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!